Aller au contenu principal
Retour à l'annuaire
Rhumatologue

Docteur JEAN LEONE

📍 Reims (51)HospitalierRPPS 10001717494
🏆 1 DU/DIU

Diplômes

🎓 DES & spécialité ordinale

  • DES Rhumatologie
  • Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

  • CES Médecine appliquée aux sports

🎯 Capacités

  • Médecine appliquée aux sports (C)

🎓 Diplômes

  • DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

🏆 DU / DIU rhumato reconnus

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib📇 Ajouter à mes contacts

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

  • 1
    Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

    Arthritis and rheumatism · 2010

    📚 306 citations🎯 RCR 8.99Top 3% NIH
    Lire l'abstract Crossref ↓

    AbstractObjectiveA number of open‐label studies have suggested the potential benefit of rituximab (RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled trials (RCTs) of RTX, the primary end points were not met. We undertook this study to evaluate the safety and efficacy of RTX in off‐trial patients with SLE seen in regular clinical practice.MethodsWe analyzed prospective data from the French AutoImmunity and Rituximab (AIR) registry, which includes data on patients with autoimmune disorders treated with RTX.ResultsOne hundred thirty‐six patients received treatment for SLE. The mean ± SD score on the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the SLE Disease Activity Index (SLEDAI) was 11.3 ± 8.9 at baseline. Severe infections were noted in 12 patients (9%), corresponding to a rate of 6.6/100 patient‐years. Most severe infections occurred within the first 3 months after the last RTX infusion. Five patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). Overall response was observed in 80 of 113 patients (71%) by the SELENA–SLEDAI assessment. Efficacy did not differ significantly between patients receiving RTX monotherapy and those receiving concomitant immunosuppressive agents (who had higher baseline disease activity). Articular, cutaneous, renal, and hematologic improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. Among responders, 41% experienced a relapse of disease, with a response in 91% after retreatment with RTX.ConclusionData from the AIR registry show a satisfactory tolerance profile and clinical efficacy of RTX in patients with SLE. The contrasting results with those from recent RCTs leave open the question of the therapeutic use of RTX in SLE. Additional controlled studies with new designs are needed to define the place of RTX in the therapeutic arsenal for SLE.

  • 2
    Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

    Annals of the rheumatic diseases · 2013

    📚 160 citations🎯 RCR 6.04Top 6% NIH
  • 3
    Predictive risk factors for stiff knees in total knee arthroplasty

    The Journal of arthroplasty · 2006

    📚 142 citations🎯 RCR 5.89Top 6% NIH

Publications scientifiques (25) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Transversal11

▼

Lupus5

▼

Biothérapies non-anti-TNF3

▼

Sjögren3

▼

Case report / série2

▼

Anti-TNF1

▼

Épidémiologie & registres1

▼

Sclérodermie1

▼

Vascularites des gros vaisseaux1

▼

Partager cette fiche

in LinkedIn🟢 WhatsApp✉ Email

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.